|
1
|
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.
|
Br J Cancer
|
1999
|
1.86
|
|
2
|
Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database.
|
J Clin Oncol
|
1998
|
1.36
|
|
3
|
Impact of race in lung cancer: analysis of temporal trends from a surveillance, epidemiology, and end results database.
|
Chest
|
2001
|
1.21
|
|
4
|
Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas.
|
Oncogene
|
1997
|
1.17
|
|
5
|
Therapeutic advances in small cell lung cancer.
|
Expert Opin Investig Drugs
|
2000
|
0.99
|
|
6
|
Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung cancer.
|
Cancer Gene Ther
|
1998
|
0.95
|
|
7
|
Lung cancer in patients < 50 years of age: the experience of an academic multidisciplinary program.
|
Chest
|
1999
|
0.92
|
|
8
|
Retinoic acid-mediated growth inhibition of small cell lung cancer cells is associated with reduced myc and increased p27Kip1 expression.
|
Int J Cancer
|
1999
|
0.89
|
|
9
|
Non-Hodgkin's lymphoma: an analysis of the Metropolitan Detroit SEER database.
|
Cancer Invest
|
2000
|
0.89
|
|
10
|
Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.
|
Cancer
|
1999
|
0.85
|
|
11
|
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.
|
Ann Oncol
|
2000
|
0.82
|
|
12
|
Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines.
|
Anticancer Res
|
1998
|
0.80
|
|
13
|
Activity of 9-cis-retinoic acid and receptor-selective retinoids in small cell lung cancer cell lines.
|
Anticancer Res
|
1999
|
0.78
|
|
14
|
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.78
|
|
15
|
Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin.
|
Biochem Pharmacol
|
1995
|
0.77
|
|
16
|
Etoposide-induced pulmonary toxicity.
|
Lung Cancer
|
1999
|
0.76
|
|
17
|
Mechanism of all-trans-retinoic acid-mediated L-myc gene regulation in small cell lung cancer.
|
Oncogene
|
1996
|
0.76
|
|
18
|
Induction of apoptosis by a short-chain neuropeptide analog in small cell lung cancer.
|
Peptides
|
1998
|
0.75
|
|
19
|
"But doctor, what have I got to lose...?".
|
J Clin Oncol
|
2001
|
0.75
|
|
20
|
Phase II study of hyperfractionated radiotherapy and concurrent weekly alternating chemotherapy in limited-stage small cell lung cancer.
|
Lung Cancer
|
1998
|
0.75
|
|
21
|
Lung cancer.
|
Cancer Treat Res
|
2001
|
0.75
|
|
22
|
Induction of gastrin releasing peptide by all-trans retinoic acid in small cell lung cancer cells.
|
Oncol Rep
|
1998
|
0.75
|
|
23
|
A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung cancer.
|
Cancer Invest
|
2000
|
0.75
|